Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 39Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Gliosarcoma 43Glioblastoma 43Brain Neoplasms 29Glioma 23Sarcoma 20Astrocytoma 13Oligodendroglioma 10Central Nervous System Neoplasms 8Colorectal Neoplasms 7Neoplasm Metastasis 6Recurrence 5Stomach Neoplasms 4Neoplasms 4Hemangiosarcoma 4Carcinoma, Hepatocellular 4Sarcoma, Kaposi 3Ovarian Neoplasms 3Osteosarcoma 3Gastrointestinal Stromal Tumors 3Sarcoma, Ewing 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leiomyosarcoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Diffuse Intrinsic Pontine Glioma 2

Interventions

tislelizumab 1spartalizumab 1sintilimab 1milademetan 1enzalutamide 1Pemetrexed 1Midazolam 1Letrozole 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fulvestrant 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × Bevacizumab × Sarcoma × Clear all
NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Terminated
9 enrolled
SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡